LIFEVANTAGE CORP Finite-Lived Intangible Assets, Net
LIFEVANTAGE CORP (LFVN) had Finite-Lived Intangible Assets, Net of $2.81 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-08-27
- 2026-06-30: Finite-Lived Intangible Assets, Net $2.81M.
- 2025-06-30: Finite-Lived Intangible Assets, Net $0.00.
- 2014-03-31: Finite-Lived Intangible Assets, Net $1.70M.
- 2013-12-31: Finite-Lived Intangible Assets, Net $1.73M.
| Period end | Finite-Lived Intangible Assets, Net | Finite-Lived Intangible Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $2.81M 10-K · filed 2026-08-27 | |
| 2025-06-30 | $0.00 10-K · filed 2026-08-27 | |
| 2014-03-31 | $1.70M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $1.73M 10-Q · filed 2014-02-06 | |
| 2013-09-30 | $1.76M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $1.75M 10-Q · filed 2014-05-06 | |
| 2013-03-31 | $1.78M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $1.81M 10-Q · filed 2013-02-07 | |
| 2012-09-30 | $1.85M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $1.88M 10-K · filed 2013-09-12 | $1.88M 10-K · filed 2012-09-10 |
| 2012-03-31 | $1.91M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $1.93M 10-Q · filed 2012-02-14 | |
| 2011-09-30 | $1.94M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $1.96M 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |